Univercells SA, a Gosselies, Belgium-based technology company dedicated to delivering innovative biomanufacturing solutions, closed a €3m ($3.56M) Series-A equity funding round.
Backers included the company’s founders, Takeda Ventures and a dozen unnamed private investors.
Founded in 2013 by Hugues Bultot, CEO, and José Castillo, CTO, Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines.
The company intends to use the funds for the commercial roll-out of its viral platform and the completion of its recombinant platform. In the coming months, the investment will support:
– the commercial roll-out of its viral micro-facility, with a first technology transfer anticipated for the fourth quarter of 2018 within the framework of the Bill & Melinda Gates Foundation-supported program; and
– the completion of its innovative recombinant platform development.